PULM — Pulmatrix, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1574235 ·
Last close
$1.59
Market Cap
$5.81M
52W High
$5.50
52W Low
$1.16
ADV30
36,457
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,046,000 | -1,036,000 | 3,246,000 | 2,168,000 | 689,000 |
| Mar 2026 | 0 | — | -1,292,000 | -1,172,000 | 4,496,000 | 3,324,000 | 905,000 |
| Dec 2025 | 0 | — | -908,000 | -928,000 | 4,139,000 | 4,088,000 | 329,000 |
| Sep 2025 | 0 | — | -866,000 | -877,000 | 4,982,000 | 4,794,000 | 249,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,687,000
Investing CF
$0
Financing CF
$1,000,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.48
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-303,490,000
Inventory
—
Receivables
$16,000
ST Investments
—
EBIT TTM
$-4,614,000
Pretax Income TTM
$-4,526,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,169,000 | -5,162,000 | 4,139,000 | 329,000 | 3,810,000 | -5,433,000 |
| Dec 2024 | 7,806,000 | -7,145,000 | -9,559,000 | 9,943,000 | 996,000 | 8,947,000 | -10,716,000 |
| Dec 2023 | 7,298,000 | -14,740,000 | -14,121,000 | 33,958,000 | 15,963,000 | 17,995,000 | -15,985,000 |
| Dec 2022 | 6,071,000 | -18,947,000 | -18,836,000 | 40,953,000 | 9,844,000 | 31,109,000 | -19,356,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals, Inc. | $5.80M | $0.06 | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $5.76M | $1.34 | — |
| GELS | Gelteq Ltd | $5.86M | $0.55 | — |
| KAPA | Kairos Pharma, LTD. | $5.69M | $1.68 | — |
| DRMA | Dermata Therapeutics, Inc. | $5.55M | $1.12 | — |
News headlines (Yahoo Finance, 1h cache)
Pulmatrix Announces First Quarter 2026 Financial Results
2026-05-15 12:20 · Yahoo
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
2026-04-21 12:00 · Yahoo
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
2026-09-22 12:30 · Yahoo
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
2026-08-13 12:15 · Yahoo
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
2026-03-26 12:00 · Yahoo
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
2026-03-26 10:46 · Yahoo
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
2026-03-02 13:00 · Yahoo
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
2025-12-18 13:05 · Yahoo
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
2025-10-16 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.